Monte Rosa Therapeutics, Inc.

GLUE

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001826457

SEC filings (opens in a new tab)

In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.

Q4 2025 vs. Q3 2025

How the institutions holding Monte Rosa Therapeutics, Inc. changed between Q3 2025 and Q4 2025.

All holders in Q4 2025 All holders in Q3 2025

13F holders of GLUE: Q3 2025 compared with Q4 2025
Measure	Q3 2025	Of which not filed for Q4 2025	Q4 2025	Change
Holders	129	1	161	+33
Shares	60.0M	591	64.5M	+4.44M (+7.4%)
Value	$444.9M	$4.38K	$1.01B	+$566.1M (+127.3%)

1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (49)

Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.

Institutions new to GLUE in Q4 2025
Institution	Shares	Value	% of portfolio
TCG Crossover Management, LLC	4,622,151	$72.5M	2.40%
MPM Oncology Impact Management LP	1,173,376	$18.4M	2.11%
Braidwell LP	948,316	$14.9M	0.48%
Arrowstreet Capital, Limited Partnership	307,651	$4.82M	0.00%
Nextech Invest, Ltd.	279,237	$4.38M	0.42%
Nomura Asset Management International Inc.	200,000	$3.14M	0.00%
Trexquant Investment LP	149,712	$2.35M	0.02%
Atom Investors LP	137,261	$2.15M	0.17%
Ameriprise Financial Inc	122,164	$1.92M	0.00%
EAM Investors, LLC	70,037	$1.10M	0.12%
Canada Pension Plan Investment Board	68,100	$1.07M	0.00%
Rafferty Asset Management, LLC	67,438	$1.06M	0.00%
Advisory Research Inc	63,220	$991.3K	0.12%
Diadema Partners LP	62,281	$976.6K	0.58%
StemPoint Capital LP	61,577	$965.5K	0.17%
Nantahala Capital Management, LLC	57,991	$909.3K	0.05%
Massachusetts Financial Services Co	49,630	$778.2K	0.00%
STRS Ohio	36,100	$566.0K	0.00%
Voloridge Investment Management, LLC	35,783	$561.1K	0.00%
J. Goldman & Co LP	32,291	$506.3K	0.02%
Aquatic Capital Management LLC	30,940	$485.1K	0.01%
Voya Investment Management LLC	26,382	$413.7K	0.00%
Profund Advisors LLC	25,219	$395.4K	0.01%
NEOS Investment Management LLC	25,137	$394.1K	0.00%
Tema ETFs LLC	24,767	$388.3K	0.03%
Creative Planning	23,403	$367.0K	0.00%
Winton Group Ltd	22,930	$359.5K	0.01%
Persistent Asset Partners Ltd	22,211	$348.3K	0.17%
Brookwood Investment Group LLC	19,535	$306.3K	0.04%
SG Americas Securities, LLC	17,279	$271.0K	0.00%
Axq Capital, LP	13,742	$215.5K	0.05%
Martingale Asset Management L P	12,413	$194.6K	0.00%
Baader Bank INC	11,000	$172.5K	0.01%
Mercer Global Advisors Inc	10,971	$172.0K	0.00%
Mayflower Financial Advisors, LLC	10,000	$156.8K	0.02%
Seven Fleet Capital Management LP	4,000	$62.7K	0.04%
GAMMA Investing LLC	1,905	$29.9K	0.00%
Federated Hermes, Inc.	1,323	$20.7K	0.00%
Rockefeller Capital Management L.P.	1,061	$16.6K	0.00%
Paladin Partners, LLC	1,000	$15.7K	0.01%
UBS Asset Management Americas Inc	570	$8.94K	0.00%
Spire Wealth Management	509	$7.98K	0.00%
Farther Finance Advisors, LLC	439	$6.88K	0.00%
Covestor Ltd	387	$6.00K	0.00%
Smartleaf Asset Management LLC	37	$591	0.00%
MAI Capital Management	33	$518	0.00%
SJS Investment Consulting Inc.	29	$455	0.00%
Caitong International Asset Management Co., Ltd	27	$423	0.00%
Sunbelt Securities, Inc.	1	$16	0.00%

Sold out (16)

Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.

Institutions that sold out of GLUE in Q4 2025
Institution	Shares, Q3 2025	Value, Q3 2025
Balyasny Asset Management LLC	408,540	$3.03M
Renaissance Technologies LLC	395,733	$2.93M
Macquarie Group Ltd	200,000	$1.48M
JBF Capital, Inc.	148,566	$1.10M
Qube Research & Technologies Ltd	147,726	$1.09M
Point72 Asset Management, L.P.	90,419	$670.0K
Mackenzie Financial Corp	77,635	$575.3K
Omers Administration Corp	28,300	$209.7K
Bailard, Inc.	22,500	$166.7K
Scientech Research LLC	16,254	$120.4K
Prudential Financial Inc	12,054	$89.3K
Two Sigma Advisers, LP	11,100	$82.3K
Royce & Associates LP	11,024	$81.7K
Engineers Gate Manager LP	10,871	$80.6K
Prelude Capital Management, LLC	10,202	$75.6K
Summit Wealth Group LLC	2,002	–

Not filed for Q4 2025 yet (1)

Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding GLUE in Q3 2025 that haven't filed for Q4 2025
Institution	Shares, Q3 2025	Value, Q3 2025
Point72 Europe (London) LLP	591	$4.38K